Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Oncogenic activated RAS mutations have been detected in 50% of de novo and 70% of relapsed multiple myeloma (MM) patients. Translocation t(11;14) involving IgH/CCDN1 and overexpression of cyclin-Ds are early events in MM pathogenesis, enhancing uncontrolled MM cell growth. We hypothesized that targeting both RAS/MAPK pathway molecules including Erk1/2 along with cyclin-Ds enhances MM cytotoxicity and minimizes side effects. Recent studies have demonstrated the high potency of Erk1/2 and CDK4/6 inhibitors in metastatic relapsed cancers, and here we tested anti-MM effects of the Erk1/2 + CDK4/6 inhibitor combination. Our studies showed strong synergistic (IC < 0.5) cytotoxicity of Erk1/2i + CDK4/6i in MM-cells. Erk1/2i + CDK4/6i treatment in a dose-dependent manner arrested MM-cells in the G0/G1 phase and activated mitochondrial apoptotic signaling. Our studies showed that Erk1/2i + CDK4/6i treatment-induced inhibition of key target molecules in Erk1/2 and CDK4/6 signaling, such as c-myc, p-RSK, p-S6, p-RB, and E2F1, suggesting on-target activity of these inhibitors. We identified Erk1/2i + CDK4/6i treatment associated five-gene signature which includes SNRPB and SLC25A5; these genes are involved in RNA processing and mitochondrial metabolism, respectively. Overall, our studies provide the preclinical framework for Erk1/2i + CDK4/6i combination clinical trials to target Ras+CDK pathways to improve patient outcome in MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mutations of KRAS and NRAS induce the activation of ERK are common in MM, and these mutations present in 23-54% with a new diagnosis, but it increases to 45-81% in RRMM patients [90–92].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [92]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis
Tai, Y.-T., Fulciniti, M., Hideshima, T., Song, W., Leiba, M., Li, X.-F., Rumizen, M., Burger, P., Morrison, A., Podar, K., et al. (2007) · Blood · doi:10.1182/blood-2007-03-081240 · Cited by 109
Self-citationRetractedCdks, cyclins and CKIs: roles beyond cell cycle regulation
Lim, S., & Kaldis, P. (2013) · Development · doi:10.1242/dev.091744 · Cited by 1,487 · cited 2×
“Activated Erk1/2 or CDK4/6 directly affects mitochondrial metabolism and potentiates the catalytic activity of some pro-apoptotic proteins [41, 42].”
BackgroundKumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,177 · cited 1×
“INTRODUCTION Despite therapeutic advances, MM remains incurable due to the high frequency of relapse and the development of drug resistance [1].”
BackgroundSelf-citationWidespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.015 · Cited by 988
Self-citationUnderstanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
Self-citationHeterogeneity of genomic evolution and mutational profiles in multiple myeloma
Bolli, N., Avet-Loiseau, H., Wedge, D. C., Van Loo, P., Alexandrov, L. B., Martincorena, I., Dawson, K. J., Iorio, F., Nik-Zainal, S., Bignell, G. R., et al. (2014) · Nature Communications · doi:10.1038/ncomms3997 · Cited by 875
Self-citationPende, M., Um, S. H., Mieulet, V., Sticker, M., Goss, V. L., Mestan, J., Mueller, M., Fumagalli, S., Kozma, S. C., & Thomas, G. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3112-3124.2004 · Cited by 742
Roux, P. P., Shahbazian, D., Vu, H., Holz, M. K., Cohen, M. S., Taunton, J., Sonenberg, N., & Blenis, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700906200 · Cited by 702 · cited 1×
“Protein S6 is a part of the 40S ribosomal subunit and can be phosphorylated by S6 kinase in the mTOR pathway in an ERK-dependent manner [57, 58].”
BackgroundMEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606 · cited 1×
“Several MEK- and CDK-inhibitors have been developed and investigated in preclinical and clinical models to target Ras/Cyclin-D pathways in MM, either single agents or in combination with conventional MM therapy [10, 11].”
BackgroundYeh, T. C., Marsh, V., Bernat, B. A., Ballard, J., Colwell, H., Evans, R. J., Parry, J., Smith, D., Brandhuber, B. J., Gross, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1150 · Cited by 578
Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577
Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases
Hydbring, P., Malumbres, M., & Sicinski, P. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.27 · Cited by 528 · cited 2×
“Activated Erk1/2 or CDK4/6 directly affects mitochondrial metabolism and potentiates the catalytic activity of some pro-apoptotic proteins [41, 42].”
BackgroundThe spliceosome is a therapeutic vulnerability in MYC-driven cancer
Hsu, T. Y.-T., Simon, L. M., Neill, N. J., Marcotte, R., Sayad, A., Bland, C. S., Echeverria, G. V., Sun, T., Kurley, S. J., Tyagi, S., et al. (2015) · Nature · doi:10.1038/nature14985 · Cited by 492 · cited 1×
“These genes encode subunits of the U1-spliceosome complex and are involved in altered RNA splicing specifically in the intron retention process, which is a unique marker of malignant transformation [43, 44].”
BackgroundSpatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
Rasche, L., Chavan, S. S., Stephens, O. W., Patel, P. H., Tytarenko, R., Ashby, C., Bauer, M., Stein, C., Deshpande, S., Wardell, C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00296-y · Cited by 417
Egan, J. B., Shi, C.-X., Tembe, W., Christoforides, A., Kurdoglu, A., Sinari, S., Middha, S., Asmann, Y., Schmidt, J., Braggio, E., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405977 · Cited by 404
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Montero, J., Sarosiek, K. A., DeAngelo, J. D., Maertens, O., Ryan, J., Ercan, D., Piao, H., Horowitz, N. S., Berkowitz, R. S., Matulonis, U., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.042 · Cited by 378
Self-citationIntron retention is a widespread mechanism of tumor-suppressor inactivation
Jung, H., Lee, D., Lee, J., Park, D., Kim, Y. J., Park, W.-Y., Hong, D., Park, P. J., & Lee, E. (2015) · Nature Genetics · doi:10.1038/ng.3414 · Cited by 339 · cited 1×
“These genes encode subunits of the U1-spliceosome complex and are involved in altered RNA splicing specifically in the intron retention process, which is a unique marker of malignant transformation [43, 44].”
BackgroundBone marrow microenvironment and the identification of new targets for myeloma therapy
Podar, K., Chauhan, D., & Anderson, K. C. (2009) · Leukemia · doi:10.1038/leu.2008.259 · Cited by 337
Self-citationMcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival
Wuillème-Toumi, S., Robillard, N., Gomez, P., Moreau, P., Le Gouill, S., Avet-Loiseau, H., Harousseau, J.-L., Amiot, M., & Bataille, R. (2005) · Leukemia · doi:10.1038/sj.leu.2403784 · Cited by 335
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.039 · Cited by 308
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388298 · Cited by 299
Kortüm, K. M., Mai, E. K., Hanafiah, N. H., Shi, C.-X., Zhu, Y.-X., Bruins, L., Barrio, S., Jedlowski, P., Merz, M., Xu, J., et al. (2016) · Blood · doi:10.1182/blood-2016-02-698092 · Cited by 255
Haura, E. B., Ricart, A. D., Larson, T. G., Stella, P. J., Bazhenova, L., Miller, V. A., Cohen, R. B., Eisenberg, P. D., Selaru, P., Wilner, K. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1920 · Cited by 237
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
Schettini, F., De Santo, I., Rea, C. G., De Placido, P., Formisano, L., Giuliano, M., Arpino, G., De Laurentiis, M., Puglisi, F., De Placido, S., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00608 · Cited by 201
RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer
Iverson, C., Larson, G., Lai, C., Yeh, L.-T., Dadson, C., Weingarten, P., Appleby, T., Vo, T., Maderna, A., Vernier, J.-M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0679 · Cited by 183
Adenine nucleotide translocase 2 is a key mitochondrial protein in cancer metabolism
Chevrollier, A., Loiseau, D., Reynier, P., & Stepien, G. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.10.008 · Cited by 181 · cited 1×
“The identified signature genes also include the SLC25A5, which facilitates ATP transfer in the inner mitochondrial membrane [30].”
BackgroundRasmussen, T., Kuehl, M., Lodahl, M., Johnsen, H. E., & Dahl, I. M. S. (2005) · Blood · doi:10.1182/blood-2004-03-0833 · Cited by 163 · cited 1×
“It is known that KRAS/NRAS-mutations are associated with disease progression, rather than MM initiating events [7].”
BackgroundCyclin dependent kinases in cancer: Potential for therapeutic intervention
Canavese, M., Santo, L., & Raje, N. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.19589 · Cited by 159
Huynh, H., Soo, K. C., Chow, P. K. H., & Tran, E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0436 · Cited by 150
O'Neil, B. H., Goff, L. W., Kauh, J. S. W., Strosberg, J. R., Bekaii-Saab, T. S., Lee, R.-M., Kazi, A., Moore, D. T., Learoyd, M., Lush, R. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9432 · Cited by 143
Cyclin-Dependent Kinase 6 Is a Chromatin-Bound Cofactor for NF-κB-Dependent Gene Expression
Handschick, K., Beuerlein, K., Jurida, L., Bartkuhn, M., Müller, H., Soelch, J., Weber, A., Dittrich-Breiholz, O., Schneider, H., Scharfe, M., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.12.002 · Cited by 141
Santo, L., Vallet, S., Hideshima, T., Cirstea, D., Ikeda, H., Pozzi, S., Patel, K., Okawa, Y., Gorgun, G., Perrone, G., et al. (2010) · Oncogene · doi:10.1038/onc.2009.510 · Cited by 139
Self-citationLentzsch, S., Chatterjee, M., Gries, M., Bommert, K., Gollasch, H., Dörken, B., & Bargou, R. C. (2004) · Leukemia · doi:10.1038/sj.leu.2403486 · Cited by 138
Soni, S., Anand, P., & Padwad, Y. S. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1115-1 · Cited by 132
Kim, K., Kong, S., Fulciniti, M., Li, X., Song, W., Nahar, S., Burger, P., Rumizen, M. J., Podar, K., Chauhan, D., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08127.x · Cited by 126
Self-citationMulligan, G., Lichter, D. I., Di Bacco, A., Blakemore, S. J., Berger, A., Koenig, E., Bernard, H., Trepicchio, W., Li, B., Neuwirth, R., et al. (2014) · Blood · doi:10.1182/blood-2013-05-504340 · Cited by 118
Self-citationEly, S., Di Liberto, M., Niesvizky, R., Baughn, L. B., Cho, H. J., Hatada, E. N., Knowles, D. M., Lane, J., & Chen-Kiang, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2159 · Cited by 115 · cited 1×
“CDK4 and CCDN1 or CDK4/6 and CCDN2 are overexpressed in MM; moreover, CDK6 overexpression (CDKN2C deletion) in MM correlates with poor overall survival [33, 53].”
BackgroundLiu, M., Liu, H., & Chen, J. (2018) · Oncology Reports · doi:10.3892/or.2018.6221 · Cited by 112 · cited 1×
“Recent studies show that CDK4/6 also induces tumorigenesis through the regulation of inflammatory cytokines induced via (NF)-κB pathway activation [59, 60].”
BackgroundBhagwat, S. V., McMillen, W. T., Cai, S., Zhao, B., Whitesell, M., Shen, W., Kindler, L., Flack, R. S., Wu, W., Anderson, B., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0183 · Cited by 107
Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications
Leone, P. E., Walker, B. A., Jenner, M. W., Chiecchio, L., Dagrada, G., Protheroe, R. K. M., Johnson, D. C., Dickens, N. J., Brito, J. L., Else, M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0347 · Cited by 103 · cited 1×
“CDK4 and CCDN1 or CDK4/6 and CCDN2 are overexpressed in MM; moreover, CDK6 overexpression (CDKN2C deletion) in MM correlates with poor overall survival [33, 53].”
BackgroundCorrea, B. R., de Araujo, P. R., Qiao, M., Burns, S. C., Chen, C., Schlegel, R., Agarwal, S., Galante, P. A. F., & Penalva, L. O. F. (2016) · Genome Biology · doi:10.1186/s13059-016-0990-4 · Cited by 101
Mikulasova, A., Wardell, C. P., Murison, A., Boyle, E. M., Jackson, G. H., Smetana, J., Kufova, Z., Pour, L., Sandecka, V., Almasi, M., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.163766 · Cited by 101 · cited 1×
“Furthermore, RAS mutations distinguish MGUS from MM, indicating their crucial role in MM transformation [49].”
BackgroundMultiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting
Slomp, A., Moesbergen, L. M., Gong, J., Cuenca, M., Borne, P. A. V. D., Sonneveld, P., Huang, D. C. S., Minnema, M. C., & Peperzak, V. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000702 · Cited by 94
Urashima, M., Teoh, G., Chauhan, D., Hoshi, Y., Ogata, A., Treon, S. P., Schlossman, R. L., & Anderson, K. C. (1997) · Blood · doi:10.1182/blood.v90.1.279 · Cited by 88
Self-citationRole and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma
Slomp, A., & Peperzak, V. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00533 · Cited by 80
SNRPB promotes the tumorigenic potential of NSCLC in part by regulating RAB26
Liu, N., Wu, Z., Chen, A., Wang, Y., Cai, D., Zheng, J., Liu, Y. U., & Zhang, L. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1929-y · Cited by 72
Signaling Pathway Mediating Myeloma Cell Growth and Survival
Hideshima, T., & Anderson, K. C. (2021) · Cancers · doi:10.3390/cancers13020216 · Cited by 70 · cited 1×
“Previous studies done by our group and others have shown MM BM milieu induced Erk1/2 activation in MM patients confers resistance to MM therapies including immunomodulatory drugs iMiDs [61, 62].”
ResultSelf-citationMEK inhibitors as a chemotherapeutic intervention in multiple myeloma
Chang-Yew Leow, C., Gerondakis, S., & Spencer, A. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.1 · Cited by 62
Adamia, S., Bar‐Natan, M., Haibe‐Kains, B., Pilarski, P. M., Bach, C., Pevzner, S. J., Calimeri, T., Avet‐Loiseau, H., Lodé, L., Verselis, S. J., et al. (2014) · Blood · doi:10.1182/blood-2013-02-481507 · Cited by 62 · cited 1×
“Protein expression Protein lysate preparation and immunoblotting analyses were carried out as previously described [31].”
MethodSelf-citationCirstea, D., Hideshima, T., Santo, L., Eda, H., Mishima, Y., Nemani, N., Hu, Y., Mimura, N., Cottini, F., Gorgun, G., et al. (2013) · Leukemia · doi:10.1038/leu.2013.194 · Cited by 59
Self-citationQin, Q., Li, X., Liang, X., Zeng, L., Wang, J., Sun, L., & Zhong, D. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13521 · Cited by 58
Huang, H. H., Ferguson, I., Thornton, A. M., Bastola, P., Lam, C., Lin, Y.-H. T., Choudhry, P., Mariano, M. C., Marcoulis, M., Teo, C. F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15521-4 · Cited by 51 · cited 1×
“Overexpression of SNRPB leads to alterations in the splicing process in MM-cells of patients treated with proteasome inhibitors (PI) [46].”
BackgroundSuzuki, R., Hideshima, T., Mimura, N., Minami, J., Ohguchi, H., Kikuchi, S., Yoshida, Y., Görgün, G., Cirstea, D. D., Cottini, F., et al. (2014) · Leukemia · doi:10.1038/leu.2014.300 · Cited by 33
Self-citationBiological Background of Resistance to Current Standards of Care in Multiple Myeloma
Mogollón, P., Díaz-Tejedor, A., Algarín, E. M., Paíno, T., Garayoa, M., & Ocio, E. M. (2019) · Cells · doi:10.3390/cells8111432 · Cited by 32 · cited 1×
“Previous studies done by our group and others have shown MM BM milieu induced Erk1/2 activation in MM patients confers resistance to MM therapies including immunomodulatory drugs iMiDs [61, 62].”
ResultSoni, S., Saroch, M. K., Chander, B., Tirpude, N. V., & Padwad, Y. S. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1167-2 · Cited by 31
Ratoša, I., Oražem, M., Scoccimarro, E., Steinacher, M., Dominici, L., Aquilano, M., Cerbai, C., Desideri, I., Ribnikar, D., Marinko, T., et al. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.05.013 · Cited by 31
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment
Liu, J., Hideshima, T., Xing, L., Wang, S., Zhou, W., Samur, M., Sewastianik, T., Ogiya, D., An, G., Gao, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg2697 · Cited by 29 · cited 1×
“to iMiDs; based on our current study, ERK1/2i+ CDK4/6i may also overcome this mechanism of IMiD induced resistance in the tumor BM microenvironment [63].”
BackgroundSelf-citationTargeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma
Guo, M., Sun, D., Fan, Z., Yuan, Y., Shao, M., Hou, J., Zhu, Y., Wei, R., Zhu, Y., Qian, J., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00722 · Cited by 28
Lin, Y.-H. T., Way, G. P., Barwick, B. G., Mariano, M. C., Marcoulis, M., Ferguson, I., Driessen, C., Boise, L., Greene, C. S., & Wiita, A. P. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000303 · Cited by 26
Li, S., Fu, J., Yang, J., Ma, H., Bhutani, D., Mapara, M. Y., Marcireau, C., & Lentzsch, S. (2020) · Blood · doi:10.1182/blood.2020006334 · Cited by 22
Wang, W., Xu, S.-W., Zhu, X.-Y., Guo, Q., Zhu, M., Mao, X., Chen, Y., Li, S.-W., & Luo, W. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.665173 · Cited by 20 · cited 11×
“Recently, Wang et al identified a novel prognostic signature in MM based on expression of eight RBP’s (RNA binding protein) which includes SNRPB [64].”
BackgroundInfluentialRole of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma
Urashima, M., Teoh, G. K. H., Ogata, A., Chauhan, D., Treon, S. P., Hoshi, Y., DeCaprio, J. A., & Anderson, K. C. (1997) · Leukemia · doi:10.1038/sj.leu.2400843 · Cited by 17 · cited 1×
“Dysregulated and increased cyclin-D expressions are early events in MM pathogenesis, enhancing MM cell responses to proliferative stimuli [8, 9].”
BackgroundSelf-citationEvaluation of ERK as a therapeutic target in acute myelogenous leukemia
Weisberg, E., Meng, C., Case, A. E., Sattler, M., Tiv, H. L., Gokhale, P. C., Buhrlage, S. J., Wang, J., Gray, N. S., Stone, R. M., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0552-3 · Cited by 17 · cited 1×
“Cell cycle analysis was performed as previously described [27].”
MethodSelf-citationThe effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma
Adamia, S., Abiatari, I., Amin, S. B., Fulciniti, M., Minvielle, S., Cheng, L., Moreau, P., Avet‐Loiseau, H., Munshi, N. C., & Anderson, K. C. (2019) · Leukemia · doi:10.1038/s41375-019-0498-5 · Cited by 16 · cited 1×
“We validated Erk1/2i+ CDK4/6i signature-gene (G-set-1/2) expression in two independent MM patient cohorts (GDS4968 and GSE5900-2658), using previously described data analyses pipeline (Table S3) [45].”
MethodSelf-citationHuang, H. H., Ferguson, I., Thornton, A. M., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/508549 · Cited by 8
Fan, L., Hong, J.-Q., Huang, H., Fu, D., Wu, S., Wang, Q., Ye, Y., & Liu, Y. (2017) · Medical Science Monitor · doi:10.12659/msm.901850 · Cited by 6
Lin, Y.-H. T., Way, G. P., Barwick, B. G., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/563312 · Cited by 4 · cited 2×
“Based on our results, we speculate that the RAS mutation is not the only factor to predict treatment response to RAS inhibitors; in this process, MAPK pathway activation plays a critical role and should be considered [40].”
BackgroundResult
Cited by
The role of NAD+ metabolism and its modulation of mitochondria in aging and disease
Yusri, K., Jose, S., Vermeulen, K. S., Tan, T. C. M., & Sorrentino, V. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00067-0 · Cited by 220
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Sigaud, R., Albert, T., Hess, C. C., Hielscher, T., Winkler, N., Kocher, D., Walter, C., Münter, D., Selt, F., Usta, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40235-8 · Cited by 43
“The increased MSS in the microglia compartment was validated in an independent pLGG scRNA-seq data 47 (Supplementary Fig.”
P2RX7 promotes osteosarcoma progression and glucose metabolism by enhancing c-Myc stabilization
Sheng, G., Gao, Y., Ding, Q., Zhang, R., Wang, T., Jing, S., Zhao, H., Ma, T., Wu, H. K., & Yang, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03985-z · Cited by 29
Hao, Q., Zhao, W., Li, Z., Lai, Y., Wang, Y., Yang, Q., & Zhang, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117465 · Cited by 14
Metadata
- Authors
- Adamia, S., Bhatt, S., Wen, K., Chyra, Z., Fell, G. G., Tai, Y.-T., Pioso, M. S., Abiatari, I., Letai, A., Dorfman, D. M., Hideshima, T., & Anderson, K. C.
- Affiliations
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Ilia State University (GE)
- Brigham and Women's Hospital (US)
- Corresponding author
- Adamia, Sophia
- Anderson, Kenneth C.
- ORCID
- Venue
- Leukemia
- Published
- 2022-01-27
- Volume
- 36
- Issue
- 4
- Pages
- 1088-1101
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC8979823
- OpenAlex
- W4210388779
- Semantic Scholar
- a593f11ac35184f76171700be3dc2291cc074919
- Cited by
- 24
- References
- 65
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 6 · 2023: 11
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-05-05)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Leukemia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- relapsed/refractory multiple myeloma, ERK1/2 inhibitor, CDK4/6 inhibitors, combination therapy, RAS/MAPK pathway, cyclin D1, synergistic cytotoxicity, G0/G1 cell cycle arrest, mitochondrial apoptosis, c-Myc, RNA processing genes, SNRPB, SLC25A5, gene expression signatures
- MeSH terms
- Breast Neoplasms, Female, Humans, Multiple Myeloma, Neoplasm Recurrence, Local, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.